Characterization of ZO-2 as a MAGUK Family Member Associated with Tight as well as Adherens Junctions with a Binding Affinity to Occludin and alpha  Catenin*

Masahiko ItohDagger , Kazumasa MoritaDagger §, and Shoichiro TsukitaDagger

From the Dagger  Department of Cell Biology, Faculty of Medicine, Kyoto University, Sakyo-ku, Kyoto 606, Japan and the § Department of Dermatology, Faculty of Medicine, Kyoto University, Sakyo-ku, Kyoto 606, Japan

    ABSTRACT
Top
Abstract
Introduction
References

ZO-2, a member of the MAGUK family, was thought to be specific for tight junctions (TJs) in contrast to ZO-1, another MAGUK family member, which is localized at TJs and adherens junctions (AJs) in epithelial and nonepithelial cells, respectively. Mouse ZO-2 cDNA was isolated, and a specific polyclonal antibody was generated using corresponding synthetic peptides as antigens. Immunofluorescence microscopy with this polyclonal antibody revealed that, similarly to ZO-1, in addition to TJs in epithelial cells, ZO-2 was also concentrated at AJs in nonepithelial cells such as fibroblasts and cardiac muscle cells lacking TJs. When NH2-terminal dlg-like and COOH-terminal non-dlg-like domains of ZO-2 (N-ZO-2 and C-ZO-2, respectively) were separately introduced into cultured cells, N-ZO-2 was colocalized with endogenous ZO-1/ZO-2, i.e. at TJs in epithelial cells and at AJs in non-epithelial cells, whereas C-ZO-2 was distributed along actin filaments. Consistently, occludin as well as alpha  catenin directly bound to N-ZO-2 as well as the NH2-terminal dlg-like portion of ZO-1 (N-ZO-1) in vitro. Furthermore, immunoprecipitation experiments revealed that the second PDZ domain of ZO-2 was directly associated with N-ZO-1. These findings indicated that ZO-2 forms a complex with ZO-1/occludin or ZO-1/alpha catenin to establish TJ or AJ domains, respectively.

    INTRODUCTION
Top
Abstract
Introduction
References

Generation and maintenance of specialized membrane domains are required for cells to exert their physiological functions, and the underlying molecular mechanisms of these processes are attracting increasing interest from cell biologists. As components of the machinery responsible for membrane specialization, a new gene family was identified which is now called the MAGUK family (membrane-associated guanylate kinase homologues) (for reviews, see Refs. 1-3). MAGUKs are multidomain proteins that consist of PDZ, SH3, and GUK (guanylate kinase-like) domains, and through their direct association with cytoplasmic domains of integral membrane proteins, they are thought to be directly involved in clustering of integral membrane proteins to create specialized membrane domains (4-7).

Simple epithelial cells contain three specialized membrane domains at the most apical part of lateral membranes for intercellular adhesion, tight junctions (TJs),1 adherens junctions (AJs) and desmosomes (8). In these domains, occludin/claudin (9-11), cadherin (12-14), and desmoglein/desmocollin (15, 16) were identified as major integral membrane proteins (adhesion molecules), respectively, but our knowledge regarding how these integral membrane proteins are sorted into three distinct junctional membrane domains is still fragmentary. To date, three MAGUKs have been shown to be associated with these intercellular junctions, and these molecules are now called ZO-1, ZO-2, and ZO-3.

ZO-1 was first identified as a peripheral membrane protein with a molecular mass of 220 kDa and was concentrated at TJs in epithelial cells (17, 18). However, in nonepithelial cells lacking TJs, such as cardiac muscle cells and fibroblasts, it was precisely colocalized with cadherins (19, 20). ZO-1 molecule is roughly divided into two functional portions: the NH2-terminal half, which shows similarity to Drosophila lethal (1) discs large-1 (dlg) consisting of three PDZ, one SH3, and one GUK domain; and the COOH-terminal half with no sequence similarity to dlg (20-22). Consistent with the subcellular distribution of ZO-1 in epithelial and nonepithelial cells, its NH2-terminal dlg-like half bound directly to the cytoplasmic domain of occludin (23, 24) as well as alpha  catenin (24) that associates with the cytoplasmic domain of cadherin via beta  catenin (25-32). However, how ZO-1 is excluded out from AJs in epithelial cells where alpha  catenin is highly concentrated remains unclear. In addition, the COOH-terminal non-dlg-like half of ZO-1 was shown to be directly associated with actin filaments in vitro as well as in vivo (24, 44).

As compared with ZO-1, our knowledge of ZO-2 is still limited. ZO-2 with a molecular mass of 160 kDa was first identified as a ZO-1-binding protein by immunoprecipitation with anti-ZO-1 mAb (33). Cloning and sequencing of dog ZO-2 cDNA revealed that it also contained a dlg-like domain containing three PDZ, one SH3, and one GUK domain at its NH2-terminal region, followed by a short COOH-terminal non-dlg-like domain (34, 35). In contrast to ZO-1, ZO-2 was reported to be absent from intercalated discs (N-cadherin-based AJs) of cardiac muscle cells and exclusively concentrated at TJs in epithelial cells using dog ZO-2-specific pAb (34). ZO-3 was also identified in ZO-1 immunoprecipitate as a phosphorylated 130-kDa peptide (36), and its cDNA was recently cloned (37).

At the initial phase of junction formation of epithelial cells, ZO-1 was precisely colocalized with cadherins in primordial spot-like AJs, where TJs were not yet assembled, and then at the later stage, ZO-1 was transferred from AJs to TJs (38). Although these findings suggest the direct involvement of ZO-1 in the establishment of two distinct membrane domains, AJs and TJs, in epithelial cells, lack of information concerning ZO-2 has hampered more direct assessment of the junction sorting mechanism at the molecular level. In this study, we isolated a mouse ZO-2 cDNA and characterized its product in detail.

    EXPERIMENTAL PROCEDURES

Cloning of Mouse ZO-2 cDNA-- Based on the human cDNA clone X104, which was later recognized as human ZO-2 cDNA (39), a partial human ZO-2 cDNA fragment (2897-3241) was obtained by RT-PCR using mRNA from human T84 cells. This fragment was used as a probe to screen a mouse lung lambda ZAP cDNA library. Eleven positive clones were isolated, one of which, clone 10, contained the entire open reading frame of mouse ZO-2.

Antibodies-- Anti-ZO-2 pAbs, pAb59 and pAb62, were raised in rabbits using synthetic peptides corresponding to the mouse ZO-2 sequences encoding amino acids 407-419 and 1093-1108, as antigens, respectively. These pAbs were affinity purified with the GST-ZO-2 fusion protein that was produced in Escherichia coli, separated by SDS-PAGE, and transferred onto nitrocellulose membranes. Mouse anti-ZO-1 mAb (T8-754) and rat anti-alpha catenin mAb (alpha 18) were generated and characterized previously (20, 40). Rat anti-E-cadherin mAb (ECCD-2) and rat anti-P-cadherin mAb (PCD-1) were generously provided by Dr. M. Takeichi (Kyoto University, Kyoto, Japan). Mouse anti-c-myc tag mAb and rabbit anti-c-myc tag pAb were purchased from MBL (Nagoya, Japan). Mouse anti-HA-tag mAb was purchased from Boehringer Mannheim (Indianapolis, IN).

Constructs and Transfection-- For expression of NH2-terminally HA-tagged proteins in mammalian cells, an oligonucleotide encoding an HA epitope was subcloned into the eukaryotic expression vector pME18S producing pME18S-HA. The cDNA fragment containing the entire open reading frame of mouse ZO-2 was produced by PCR. The amplified product was digested with StuI and SalI, then subcloned into EcoRV/SalI-cleaved pME18S-HA. The cDNA fragments encoding the NH2-terminal dlg-like portion (1-938), COOH-terminal non-dlg-like portion (939-1167) (see Fig. 1), and other deletion mutants of the NH2-terminal dlg-like portion of mouse ZO-2 (see Fig. 6) were generated by PCR using appropriate primers and subcloned into pME18S-HA. MDCKII and 3Y1 cells were transfected with each expression vector and selected as described previously (24).

Immunofluorescence Microscopy-- Cells plated on glass coverslips were rinsed in PBS and fixed with 1% formaldehyde in PBS for 15 min at room temperature. The fixed cells were processed for immunofluorescence microscopy as described previously (24).

Production of the NH2- and COOH-terminal Portions of ZO-2 by Recombinant Baculovirus Infection-- The cDNA fragment encoding the NH2-terminal portion (1-938) or COOH-terminal portion of ZO-2 (939-1167) was generated by PCR as described above. These fragments were subcloned into the pBlueBac vector (Invitrogen) and then integrated into the baculovirus genome. The recombinant virus carrying each cDNA was isolated and condensed using a MAXBAC kit (Invitrogen). Insect Sf9 cells were infected with recombinant viruses, and the total cell lysate was prepared as described previously (24).

In Vitro Binding Assay Using GST Fusion Proteins-- GST fusion proteins with full-length alpha  catenin (GST-alpha catenin) or the cytoplasmic domain of occludin (GST-Oc358) were prepared as described previously (24). Fusion proteins were expressed in E. coli and purified using glutathione-Sepharose 4B beads (Pharmacia LKB Biotechnology, Uppsala, Sweden). Aliquots of 200 µl of glutathione-Sepharose beads slurry containing GST fusion proteins were washed with 100 volumes of PBS containing 0.1% Triton X-100, 2 mM phenylmethylsulfonyl fluoride, and 4 µg/ml leupeptin by brief centrifugation, and then 2 ml of the lysate of Sf9 cells expressing N-ZO-1 or N-ZO-2 was added, followed by incubation for 3 h at 4 °C. The beads were then washed with 40 volumes of the same solution, and bound proteins were eluted with 1 ml of 50 mM Tris-HCl buffer (pH 8.0) containing 10 mM glutathione. The amounts of GST fusion proteins in each eluate were determined by SDS-PAGE. An appropriate amount of each eluate was again applied to SDS-PAGE to contain the same amount of GST fusion proteins.

For biotinylation of the Sf9 cell lysate, Sulfo-NHS-biotin (Pierce) was added to the lysate at a final concentration of 0.5 mg/ml and incubated for 10 min at room temperature. The reaction was stopped by adding Tris-HCl (pH 8.0) up to 50 mM. To detect biotinylated proteins bound to GST-alpha catenin, each eluate was separated by SDS-PAGE, transferred onto nitrocellulose membranes, followed by incubation with alkaline phosphatase-conjugated streptavidin.

Immunoprecipitation-- Confluent monolayers of cultured cells on 9-cm dishes were washed three times with ice-cold PBS, and then cells were lysed in 2 ml of extraction buffer (PBS containing 0.5% Nonidet P-40, 2 mM phenylmethylsulfonyl fluoride, 2 mg/ml leupeptin). Cell lysates were clarified by centrifugation at 100,000 × g for 30 min and incubated with 100 µl of protein G-Sepharose bead slurry (Zymed Laboratories Inc., San Francisco, CA) coupled with mouse anti-HA mAb for 3 h at 4 °C. As a control, nonspecific mouse IgG was coupled to the beads. After five washes with the extraction buffer, immunoprecipitates were eluted with SDS-PAGE sample buffer. For metabolic labeling of transfectants, cells were washed once with methionine-free medium supplemented with 2% fetal calf serum and then incubated with 3 ml of the same medium containing 0.2 mCi [35S]methionine (Amersham Pharmacia Biotech, Buckinghamshire, UK) for 3 h before lysis.

Gel Electrophoresis and Immunoblotting-- One-dimensional SDS-PAGE (10-12.5% gel) was performed based on the method of Laemmli (41), and immunoblotting was performed as described previously (21).

    RESULTS

Isolation of Mouse ZO-2 cDNA and Generation of Anti-ZO-2 pAb-- When we began this study, only a partial dog ZO-2 cDNA had been isolated (34). Similarity searches in data bases identified a human cDNA (X104) which showed marked similarity to dog ZO-2 cDNA (39). Based on this sequence, we isolated a part of human ZO-2 cDNA by PCR using the first strand cDNA generated from total RNA of cultured human epithelial cells (T84). Using this cDNA fragment as a probe, we screened a lambda ZAP cDNA library of mouse lung, and obtained a full-length cDNA encoding mouse ZO-2 (data are available from GenBank/EBI/DDBJ under accession number AF113005). Its open reading frame encoded a protein of 1,167 amino acids with a calculated molecular mass of 132 kDa. During the course of this study, however, a full-length cDNA encoding dog ZO-2 was reported (35). Mouse ZO-2 was 85% identical to dog ZO-2 at the amino acid sequence level, and consisted of three PDZ, one SH3, and one GUK domain from the NH2-terminal end (Fig. 1).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 1.   ZO-2 constructs. HA-tagged full-length ZO-2 (F-ZO-2), HA-tagged NH2-terminal dlg-like portion of ZO-2 (N-ZO-2), and COOH-terminal non-dlg-like portion of ZO-2 (C-ZO-2) are schematically drawn. A HA sequence (HA) was tagged to the NH2 terminus of each molecule. F-ZO-2 contains three PDZ domains (PDZ1-3), one SH3 domain (SH3), and one guanylate kinase-like domain (GUK).

Based on the deduced amino acid sequence of mouse ZO-2, we synthesized two polypeptides corresponding to the middle and COOH-terminal end portions of ZO-2 that showed no sequence similarity to ZO-1 and raised pAbs (pAb59 and pAb62, respectively) in rabbits using them as antigens. Because both pAbs showed the same properties on immunoblotting as well as immunofluorescence microscopy, we will report here only the data obtained with pAb59. As shown in Fig. 2a, the affinity-purified pAb59 specifically recognized recombinant ZO-2 but not recombinant ZO-1 produced in Sf9 cells by baculovirus infection.


View larger version (33K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of ZO-2. a, specificity of anti-mouse ZO-2 pAb, pAb59. The lysates of Sf9 cells expressing full-length ZO-1 (arrowhead in ZO-1 lysate) or ZO-2 (arrowhead in ZO-2 lysate) were immunoblotted with anti-ZO-1 mAb or anti-ZO-2 pAb, pAb59. CBB, Coomassie Brilliant Blue. b, expression of ZO-1 and ZO-2 in cultured cells. The total lysates of dog epithelial cells (MDCK), mouse epithelial cells (MTD-1A), rat fibroblasts (3Y1), mouse fibroblasts (NIH 3T3, Swiss 3T3, L), and mouse myeloma cells (P3) were immunoblotted with anti-ZO-1 mAb or anti-ZO-2 pAb, pAb59.

Subcellular Distribution of ZO-2 in Comparison with ZO-1 in Cultured Cells and Tissues-- Using the affinity-purified anti-ZO-2 pAb, we first examined the expression levels of ZO-2 in various cultured cells by immunoblotting and compared them with those of ZO-1 (Fig. 2b). As previously reported, ZO-1 was detected in all the cell types examined including epithelial, fibroblastic, and myeloma cells. ZO-2 was also detected in cultured epithelial cells as well as in fibroblasts such as 3Y1, NIH 3T3, and Swiss 3T3 cells, but not in L fibroblasts or P3 myeloma cells.

We next examined the subcellular localization of ZO-2 in cultured MDCK cells and 3Y1 cells using affinity-purified anti-ZO-2 pAb. In MDCK cells, as expected from previous studies, ZO-2 was precisely colocalized with ZO-1 in a linear pattern at cell-cell borders, and computer-generated cross-sectional views confirmed that ZO-2 was colocalized with occludin at TJs and concentrated more apically than E-cadherin (data not shown). Interestingly, ZO-2 was also precisely colocalized with ZO-1 in a punctate or serrated pattern at cell-cell borders of 3Y1 fibroblasts lacking TJs (Fig. 3, a and b). This characteristic distribution of ZO-2 was identical to P-cadherin (Fig. 3, c and d). This finding prompted us to re-examine the expression and subcellular distribution of ZO-2 in cardiac muscle cells. Frozen sections were doubly stained with anti-ZO-1 mAb and affinity-purified anti-ZO-2 pAb, and intense signals of ZO-2 as well as ZO-1 were detected from intercalated discs (Fig. 3, e and f). This ZO-2 signal was specific because it was not observed on staining with pAb preabsorbed with GST-ZO-2 fusion protein (data not shown).


View larger version (152K):
[in this window]
[in a new window]
 
Fig. 3.   Colocalization of ZO-2 with ZO-1 in nonepithelial cells. Rat 3Y1 fibroblasts were doubly stained with mouse anti-ZO-1 mAb (a)/rabbit anti-ZO-2 pAb (b), or with rat anti-P-cadherin mAb (c)/rabbit anti-ZO-2 pAb (d). Frozen sections of rat hearts were doubly stained with mouse anti-ZO-1 mAb (e) and rabbit anti-ZO-2 pAb (f). Both ZO-1 and ZO-2 were co-concentrated at intercalated discs (arrows), whereas ZO-2 signal was very weak from ZO-1-positive blood vessels (arrowheads). Bars, 10 µm.

Characterization of Dlg-like and Non-dlg-like Domains of ZO-2 in Vivo and in Vitro-- Previously, we divided ZO-1 into the NH2-terminal half dlg-like (N-ZO-1) and COOH-terminal half non-dlg-like (C-ZO-1) portions and characterized them both in vivo and in vitro (24). In this study, the full-length ZO-2 (F-ZO-2) was also divided into the NH2-terminal dlg-like (N-ZO-2) and COOH-terminal non-dlg-like (C-ZO-2) domains (see Fig. 1). First, F-ZO-2, N-ZO-2, and C-ZO-2 were tagged with HA peptide at their NH2 ends and introduced into cultured MDCK cells as well as 3Y1 cells (Fig. 4). Under transient expression conditions, immunofluorescence microscopy with anti-HA mAb revealed that in both MDCK and 3Y1 cells, F-ZO-2 as well as N-ZO-2 were recruited to the cell-cell borders where endogenous ZO-2 was concentrated, i.e. TJs in MDCK cells and P-cadherin-based spot AJs in 3Y1 cells (Fig. 4, a-d). In marked contrast, C-ZO-2 appeared to be colocalized with actin filaments. In 3Y1 fibroblasts, C-ZO-2 was clearly distributed along stress fibers (Fig. 4f), although in MDCK cells it was distributed diffusely with some concentration at cell-cell borders (along circumferential actin bundles) and plasma membranes (along microvilli) (Fig. 4e).


View larger version (109K):
[in this window]
[in a new window]
 
Fig. 4.   Subcellular distribution of F-ZO-2, N-ZO-2, and C-ZO-2 in cultured epithelial (MDCK) and fibroblastic (3Y1) cells. HA-tagged full-length ZO-2 (F-ZO-2; a and b), NH2-terminal dlg-like portion of ZO-2 (N-ZO-2; c and d), and COOH-terminal non-dlg-like portion of ZO-2 (C-ZO-2; e and f) were introduced into MDCK (a, c, and e) and 3Y1 cells (b, d, and f), and transient expression of these proteins was detected using anti-HA mAb. Transfected cells are surrounded by untransfected cells that are not visible by immunostaining. Bars, 10 µm.

We have previously reported that N-ZO-1 directly binds to the cytoplasmic domain of occludin as well as alpha  catenin in vitro (24). The binding of N-ZO-2 to occludin and/or alpha  catenin was compared with that of N-ZO-1 (Fig. 5). N-ZO-1 and N-ZO-2 were produced in Sf9 cells by baculovirus infection, and the cell lysate of Sf9 cells containing almost the same amounts of N-ZO-1 or N-ZO-2 was incubated with a GST fusion protein with the cytoplasmic domain of occludin (Fig. 5a). CBB staining of the eluates from the GST/occludin fusion protein beads revealed that the cytoplasmic domain of occludin directly bound to N-ZO-2 as well as N-ZO-1. Next, we examined the binding of N-ZO-2 to alpha  catenin, but in this case the electrophoretic mobilities of recombinant N-ZO-2 (and also that of N-ZO-1) were almost the same as that of GST-alpha catenin fusion protein, making it difficult to estimate the amount of bound N-ZO-2 (and of bound N-ZO-1) by CBB staining (Fig. 5b). Thus, the total proteins of Sf9 cells containing almost the same amounts of N-ZO-1 or N-ZO-2 were biotinylated, then the in vitro binding assay with GST-alpha catenin fusion protein was performed. The amounts of bound N-ZO-1 and N-ZO-2 were estimated by detection with alkaline phosphatase-avidin. As shown in Fig. 5b, GST-alpha catenin fusion proteins bound directly to N-ZO-2 as well as N-ZO-1.


View larger version (35K):
[in this window]
[in a new window]
 
Fig. 5.   Association of N-ZO-2 with the cytoplasmic domain of occludin as well as alpha  catenin. a, occludin binding assay. GST/Occ, GST fusion protein with the cytoplasmic domain of occludin (G); N-ZO-1 Sf9-lysate, lysate of Sf9 cells expressing N-ZO-1 (arrow); N-ZO-2 Sf9-lysate, lysate of Sf9 cells expressing N-ZO-2 (arrowhead); GST/Occ-bound N-ZO-1, glutathione eluate from the mixture of GST/Occ and N-ZO-1 Sf9-lysate; GST/Occ-bound N-ZO-2, glutathione eluate from the mixture of GST/Occ and N-ZO-2 Sf9-lysate; GST+N-ZO-1, glutathione eluate from the mixture of GST and N-ZO-1 Sf9-lysate; GST+N-ZO-2, glutathione eluate from the mixture of GST and N-ZO-2 Sf9-lysate. b, alpha  catenin binding assay. Biotinylated N-ZO-1 Sf9-lysate, biotinylated lysates of Sf9 cells expressing N-ZO-1 (arrow); Biotinylated N-ZO-2 Sf9-lysate, biotinylated lysates of Sf9 cells expressing N-ZO-2 (arrowhead); GST/alpha cat, GST fusion protein with alpha  catenin (G); GST/alpha cat-bound N-ZO-1, glutathione eluate from the mixture of GST/alpha cat and biotinylated N-ZO-1 Sf9-lysate; GST/alpha cat-bound N-ZO-2, glutathione eluate from the mixture of GST/alpha cat and biotinylated N-ZO-2 Sf9-lysate; GST+N-ZO-1, glutathione eluate from the mixture of GST and biotinylated N-ZO-1 Sf9-lysate; GST+N-ZO-2, glutathione eluate from the mixture of GST and biotinylated N-ZO-2 Sf9-lysate. Each eluate was examined by Coomassie Brilliant Blue staining (CBB staining) or by detection with alkaline phosphatase-avidin (AP-avidin). Bars indicate molecular masses of 200, 116, 97, 66, 45, and 31 kDa, respectively, from the top.

Interaction of ZO-2 with ZO-1-- Because ZO-2 was first identified in the ZO-1 immunoprecipitate (33), ZO-1 is thought to be directly associated with ZO-2. Recently, the ZO-2 binding domain on ZO-1 was narrowed down to its PDZ2 domain (44). We attempted to identify the ZO-1 binding domain on ZO-2. First, we examined the in vitro binding of GST fusion proteins with N-ZO-1 or C-ZO-1 with recombinant N-ZO-2 or C-ZO-2 produced in Sf9 cells, but we detected no significant binding. These findings suggested that some modifications on ZO-1 or ZO-2 molecules within cells are required for the ZO-1/ZO-2 interaction. Therefore, we introduced HA-tagged F-ZO-2 cDNA into EL cells (L cells transfected with E-cadherin) expressing myc-tagged N-ZO-1 (NZ-EL cells) or myc-tagged C-ZO-1 (CZ-EL cells), and F-ZO-2 in the total cell lysate was immunoprecipitated with anti-HA mAb. As shown in Fig. 6a by immunoblotting with anti-myc mAb, N-ZO-1 but not C-ZO-1 was co-immunoprecipitated with F-ZO-2, indicating that the NH2-terminal dlg-like domain of ZO-1 bound to F-ZO-2. When HA-tagged C-ZO-2 cDNA was introduced into NZ-EL cells or CZ-EL cells, neither N-ZO-1 or C-ZO-1 was co-immunoprecipitated with C-ZO-2, indicating that the NH2-terminal dlg-like domain of ZO-2 is responsible for ZO-1 binding (data not shown). Then, to further narrow down the domain responsible for the ZO-1 binding, various deletion constructs of N-ZO-2 were introduced into NZ-EL cells (Fig. 6b). Each construct was tagged with HA at its NH2-end. Stable transfectants were metabolically labeled with [35S]methionine and solubilized, and then mutant ZO-2 produced from these constructs was immunoprecipitated with anti-HA mAb. As shown in Fig. 6b, N-ZO-1 was co-immunoprecipitated only when the introduced N-ZO-2 constructs contained the PDZ2 domain, indicating that the PDZ2 domain of ZO-2 is responsible for ZO-1/ZO-2 interaction.


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 6.   ZO-1/ZO-2 interaction. a, association of F-ZO-2 with N-ZO-1. F-ZO-2 (with HA-tag) cDNA was introduced into NZ-EL (NZ-EL) or CZ-EL (CZ-EL) cells that expressed E-cadherin and N-ZO-1 or C-ZO-1 (with myc-tag), respectively. When F-ZO-2 was immunoprecipitated with anti-HA mAb, N-ZO-1 (N-ZO-1) but not C-ZO-1 was co-immunoprecipitated with F-ZO-2 (arrowhead), which was confirmed by immunoblotting with anti-myc pAb. Arrows, IgG. b, domain of ZO-2 responsible for ZO-1 interaction. Various HA-tagged deletion N-ZO-2 constructs (as schematically shown above the panel) were introduced into NZ-EL cells. After stable transfectants were metabolically labeled with [35S] methionine, each ZO-2 construct (1-7) was immunoprecipitated with anti-HA mAb and examined by autoradiography. N-ZO-1 (arrowheads) was co-immunoprecipitated only with bands 2, 5 and 6 which contained the PDZ2 domain.


    DISCUSSION

ZO-1 is expressed not only in epithelial/endothelial cells but also in nonepithelial/endothelial cells such as cardiac muscle cells, fibroblasts, and astrocytes (19, 20, 42) and that, in these nonepithelial/endothelial cells, ZO-1 is precisely colocalized with cadherins (19, 20). In contrast to the ubiquitous expression and the peculiar subcellular distribution of ZO-1, ZO-2, another MAGUK family member, was reported to be specific for TJs, and to be absent from AJs in cardiac muscle cells (34). However, in the present study using anti-ZO-2 pAb, we found that ZO-2 was precisely co-concentrated with ZO-1 at intercalated discs (AJs). At present, the reason for this discrepancy remains unclear, but the following observations favored the notion that ZO-2 is very similar to ZO-1 in terms of AJ-association in nonepithelial/endothelial cells. First, a human cDNA called X104, which was later recognized to be human ZO-2 cDNA, was ubiquitously detected in various tissues and was abundant in heart (39). Second, our anti-ZO-2 pAb also detected concentration of ZO-2 at the P-cadherin-based spot-like AJs in cultured fibroblasts, which had not been examined in the previous report (34). Third, when HA-tagged F-ZO-2 and N-ZO-2 were introduced into cultured fibroblasts, it was correctly targeted to the P-cadherin-based spot-like AJs.

Our previous study suggested that ZO-1 functions as a cross-linker between occludin and actin filaments in epithelial/endothelial cells or between alpha  catenin and actin filaments in nonepithelial/endothelial cells (24). The present study revealed that the cytoplasmic domain of occludin and alpha  catenin also bound to N-ZO-2 in vitro. Exogenously expressed C-ZO-2 was distributed along stress fibers in cultured fibroblasts similarly to exogenously expressed C-ZO-1. From these observations, we concluded that ZO-2 is very similar to ZO-1 also as a cross-linker. At present, it remains unknown why two similar cross-linkers, ZO-1 and ZO-2, exist in intercellular junctions such as AJs and TJs. Furthermore, the recent knockout study of occludin revealed that ZO-1 is still exclusively concentrated at occludin-deficient TJs (43). Preliminary experiments revealed that ZO-2 also remained at occludin-deficient TJs (data not shown). These findings indicate that ZO-1 as well as ZO-2 are recruited to normal TJs through direct or indirect interactions not only with occludin but also with other TJ-specific membrane proteins such as the recently identified claudins (10).

The possible interaction of ZO-1 and ZO-2 would make the relationship of these two similar cross-linker proteins more complex. Recent immunoprecipitation analyses indicated that the PDZ2 domain of ZO-1 was responsible for ZO-1/ZO-2 interaction although it was not clear whether this interaction was direct or indirect (44). L cells and their transfectants gave a good model in which to examine the ZO-1/ZO-2 interaction because they lack endogenous expression of ZO-2. In the present study, immunoprecipitation experiments using metabolically labeled cells demonstrated that N-ZO-1 binds to the PDZ2 domain of ZO-2. Of course, although the possibility cannot be completely excluded that a third protein mediates this binding, these findings favored the notion that ZO-1 and ZO-2 directly form a heterodimer (or oligomer) through PDZ2/PDZ2 interaction. This type of PDZ/PDZ interaction has been reported between neuronal nitric oxide synthase and PSD-95 (or PSD-93) (45).

In this study, two intercellular-associated MAGUK family members, ZO-1 and ZO-2, were compared in detail. The elucidation of the molecular mechanism behind the peculiar behavior of ZO-1 and ZO-2, i.e. their respective localization at TJs and AJs in epithelial/endothelial and nonepithelial/endothelial cells, is necessary to better understand the molecular mechanism not only underlying the establishment of intercellular junction domains but also that behind the polarization of epithelial/endothelial cells. Because information concerning the molecular components of intercellular junctions is rapidly accumulating, further analyses of ZO-1 and ZO-2 including knocking-out their genes will lead to a better understanding of the physiological functions of MAGUK family members in general.

    ACKNOWLEDGEMENTS

We thank all the members of our laboratory (Dept. of Cell Biology, Faculty of Medicine, Kyoto University) for helpful discussions. We also thank K. Kamikubo-Tsuchihashi for excellent technical assistance.

    FOOTNOTES

* This study was supported in part by a Grant-in-Aid for Cancer Research and a Grant-in-Aid for Scientific Research (A) from the Ministry of Education, Science and Culture of Japan (to S. T.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) AF113005.

To whom correspondence should be addressed: Dept. of Cell Biology, Kyoto University Faculty of Medicine, Konoe-Yoshida, Sakyo-ku, Kyoto 606, Japan. Tel.: 81-75-753-4372; Fax: 81-75-753-4660; E-mail: htsukita{at}mfour.med.kyoto-u.ac.jp.

    ABBREVIATIONS

The abbreviations used are: TJ, tight junction; AJ, adherens junction; N-ZO-2, NH2-terminal dlg-like domain of ZO-2; C-ZO-2, COOH-terminal non-dlg-like domain of ZO-2; F-ZO-2, full-length ZO-2; mAb, monoclonal antibody; pAb, polyclonal antibody; RT-PCR, reverse transcriptase polymerase chain reaction; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; GST, glutathione S-transferase; HA, hemagglutinin; MDCK, Madin-Darby canine kidney.

    REFERENCES
Top
Abstract
Introduction
References
  1. Woods, D. A., and Bryant, P. J. (1993) Mech. Dev. 44, 85-89[CrossRef][Medline] [Order article via Infotrieve]
  2. Kim, S. K. (1995) Curr. Opin. Cell Biol. 7, 641-649[CrossRef][Medline] [Order article via Infotrieve]
  3. Anderson, J. M. (1995) Biochem. Soc. Trans. 23, 470-475[Medline] [Order article via Infotrieve]
  4. Kim, E., Niethammer, M., Rothschild, A., Jan, Y. N., and Sheng, M. (1995) Nature 378, 85-88[CrossRef][Medline] [Order article via Infotrieve]
  5. Kornau, H. C., Schenker, L. T., Kennedy, M. B., and Seeburg, P. H. (1995) Science 269, 1737-1740[Medline] [Order article via Infotrieve]
  6. Niethammer, M., Kim, E., and Sheng, M. (1996) J. Neurosci. 16, 2157-2163[Abstract]
  7. Irie, M., Hata, Y., Takeuchi, M., Ichtchenko, K., Toyoda, A., Hirao, K., Takai, Y., Rosahl, T. W., and Sudhof, T. C. (1997) Science 277, 1511-1515[Abstract/Free Full Text]
  8. Farquhar, M. G., and Palade, G. E. (1963) J. Cell Biol. 17, 375-409[Abstract/Free Full Text]
  9. Furuse, M., Hirase, T., Itoh, M., Nagafuchi, A., Yonemura, S., Tsukita, S., and Tsukita, S. (1993) J. Cell Biol. 123, 1777-1788[Abstract]
  10. Furuse, M., Fujita, K., Hiiragi, T., Fujimoto, K., and Tsukita, S. (1998) J. Cell Biol. 141, 1539-1550[Abstract/Free Full Text]
  11. Ando-Akatsuka, Y., Saitou, M., Hirase, T., Kishi, M., Sakakibara, A., Itoh, M., Yonemura, S., Furuse, M., and Tsukita, S. (1996) J. Cell Biol. 133, 43-47[Abstract]
  12. Boller, K., Vestweber, D., and Kemler, R. (1985) J. Cell Biol. 100, 327-332[Abstract]
  13. Takeichi, M. (1991) Science 251, 1451-1455[Medline] [Order article via Infotrieve]
  14. Kemler, R. (1992) Semin. Cell Biol. 3, 149-155[Medline] [Order article via Infotrieve]
  15. Holton, J. L., Kenny, T. P., Legan, P. K., Collins, J. E., Keen, J. N., Sharma, R., and Garrod, D. R. (1990) J. Cell Sci. 97, 239-246[Abstract]
  16. Koch, P. J., Walsh, M. J., Schmelz, M., Goldschmidt, M. D., Zimbelmann, R., and Franke, W. W. (1990) Eur. J. Cell Biol. 53, 1-12[Medline] [Order article via Infotrieve]
  17. Stevenson, B. R., Siliciano, J. D., Mooseker, M. S., and Goodenough, D. A. (1986) J. Cell Biol. 103, 755-766[Abstract]
  18. Anderson, J. M., Stevenson, B. R., Jesaitis, L. A., Goodenough, D. A., and Mooseker, M. S. (1988) J. Cell Biol. 106, 1141-1149[Abstract]
  19. Itoh, M., Yonemura, S., Nagafuchi, A., Tsukita, Sa., and Tsukita, Sh. (1991) J. Cell Biol. 115, 1449-1462[Abstract]
  20. Itoh, M., Nagafuchi, A., Yonemura, S., Kitani-Yasuda, T., Tsukita, Sa., and Tsukita, Sh. (1993) J. Cell Biol. 121, 491-502[Abstract]
  21. Tsukita, Sh., Itoh, M., Nagafuchi, A., Yonemura, S., and Tsukita, Sa. (1993) J. Cell Biol. 123, 1049-1053[Medline] [Order article via Infotrieve]
  22. Willott, E., Balda, M. S., Fanning, A. S., Jameson, B., Van Itallie, C., and Anderson, J. M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 7834-7831[Abstract/Free Full Text]
  23. Furuse, M., Itoh, M., Hirase, T., Nagafuchi, A., Yonemura, S., Tsukita, Sa., and Tsukita, Sh. (1994) J. Cell Biol. 127, 1617-1626[Abstract]
  24. Itoh, M., Nagafuchi, A., Moroi, S., and Tsukita, Sh. (1997) J. Cell Biol. 138, 181-192[Abstract/Free Full Text]
  25. Ozawa, M., Baribault, H., and Kemler, R. (1989) EMBO J. 8, 1711-1717[Abstract]
  26. Nagafuchi, A., and Takeichi, M. (1988) EMBO J. 7, 3679-3684[Abstract]
  27. Ozawa, M., and Kemler, R. (1992) J. Cell Biol. 116, 989-996[Abstract]
  28. Aberle, H., Butz, S., Stappert, J., Weissig, H., Kemler, R., and Hoschuetzky, H. (1994) J. Cell Sci. 107, 3655-3663[Abstract/Free Full Text]
  29. Hinck, L., Näthke, I. S., Papkoff, J., and Nelson, W. J. (1994) J. Cell Biol. 125, 1327-1340[Abstract]
  30. Näthke, I. S., Hinck, L., Swedlow, J. R., Papkoff, J., and Nelson, W. J. (1994) J. Cell Biol. 125, 1341-1352[Abstract]
  31. Oyama, T., Kanai, Y., Ochiai, A., Akimoto, S., Oda, T., Yanagihara, K., Nagafuchi, A., Tsukita, Sh., Shibamoto, S., Ito, F., et al.. (1994) Cancer Res. 54, 6282-6287[Abstract]
  32. Jou, T. S., Stewart, D. B., Stappart, J., Nelson, W. J., and Marrs, J. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 5067-5071[Abstract]
  33. Gumbiner, B., Lowenkopf, T., and Apatira, D. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 3460-3464[Abstract]
  34. Jesaitis, L. A., and Goodenough, D. A. (1994) J. Cell Biol. 124, 949-961[Abstract]
  35. Beatch, M., Jesaitis, L. A., Gallin, W. J., Goodenough, D. A., and Stevenson, B. R. (1996) J. Biol. Chem. 271, 25723-25726[Abstract/Free Full Text]
  36. Balda, M. S., González-Mariscal, L., Matter, K., Cereijido, M., and Anderson, J. M. (1993) J. Cell Biol. 123, 293-302[Abstract]
  37. Haskins, J., Gu, L., Wittchen, E. S., Hibbard, J., and Stevenson, B. R. (1998) J. Cell Biol. 141, 199-208[Abstract/Free Full Text]
  38. Yonemura, S., Itoh, M., Nagafuchi, A., and Tsukita, Sh. (1995) J. Cell Sci. 108, 127-142[Abstract/Free Full Text]
  39. Duclos, F., Rodius, F., Rogemann, K. W, Mandel, J. L., and Koenig, M. (1994) Hum. Mol. Genet. 3, 909-914[Abstract]
  40. Nagafuchi, A., Takeichi, M., and Tsukita, Sh. (1991) Cell 65, 849-857[Medline] [Order article via Infotrieve]
  41. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
  42. Howarth, A. G., Singer, K. L., and Stevenson, B. R. (1994) J. Membr. Biol. 137, 261-270[Medline] [Order article via Infotrieve]
  43. Saitou, M., Fujimoto, K., Doi, Y., Itoh, M., Fujimoto, T., Furuse, M., Takano, H., Noda, T., and Tsukita, Sh. (1998) J. Cell Biol. 141, 397-408[Abstract/Free Full Text]
  44. Fanning, A. S., Jameson, B. J., Jesaitis, L. A., and Anderson, J. M. (1998) J. Biol. Chem. 273, 29745-29753[Abstract/Free Full Text]
  45. Brenman, J. E., Chao, D. S., Gee, S. H., McGee, A. W., Craven, S. E., Santillano, D. R., Wu, Z., Huang, F., Xia, H., Peters, M. F., Froehner, S. C., and Bredt, D. S. (1996) Cell 84, 757-767[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.